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a positive correlation between serum amyloid 
β levels and depressive symptoms among 
community-dwelling elderly individuals in Japan
Background: Amyloid beta (Aβ) levels have been associated with an increased risk of 
Alzheimer’s disease (AD). As depression is common before the onset of AD, serum Aβ 
levels could be associated with depressive symptoms. The aim of this study was to investigate 
whether serum Aβ levels are associated with depressive symptoms and/or cognitive function 
in community-dwelling elderly individuals.
Methods: We examined the association between serum Aβ levels and depression among 
419 Japanese community-dwelling elderly individuals aged 60 years and over. Subjects were 
divided into two subgroups: younger elderly between 60 and 69 years old and older elderly 
over 69 years old. The Mini-Mental State Examination (MMSE) was used to assess cognitive 
function, and symptoms of depression were assessed using the Center for Epidemiologic Studies 
Depression Scale (CES-D). The ability to perform activities of daily living was evaluated using 
the Tokyo Metropolitan Institute of Gerontology Index of Competence. Serum Aβ levels were 
measured with a human amyloid beta enzyme-linked immunosorbent assay kit. 
Results: After controlling for potential confounding variables, a multiple linear regression 
analysis showed that increased levels of serum Aβ40 and Aβ42 were associated with higher 
CES-D scores in the older elderly subgroup. Under the same condition, multiple regression 
showed that serum Aβ levels were not associated with MMSE scores among the total subjects, 
younger elderly, or older elderly.
Conclusion: Serum Aβ levels were associated with depressive symptoms in community-
dwelling elderly individuals. The present study indicates the possibility that serum Aβ may be 
involved in the development of late-onset depression.
Keywords: Alzheimer’s disease, depression, dementia, Japanese
Introduction
Depression is a serious affective illness with heterogeneous etiologies and underlying 
pathologies.1–3 The unsatisfactory results of antidepressant medication and the high 
prevalence of somatic symptoms and physical illness in patients with depression 
imply that the serotonin hypothesis cannot fully explain the etiology of depression.4 In 
particular, late-onset depression is heterogeneous and requires various interventions,5 
and different pathogenic processes are thought to occur between younger elderly and 
older elderly individuals with depression.6,7
Recently, an association between depression and cognitive impairment or dementia 
has been recognized.8,9 Although the mechanisms are not fully understood, a meta-
analysis of studies concerning the association between depression and dementia showed 
that a history of depression significantly increased the risk of Alzheimer’s disease 
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(AD) by twofold.10 AD is characterized by the presence of 
extracellular neuritic plaques and intracellular neurofibril-
lary tangles in the brain. Two major components of neuritic 
plaques, amyloid β1-40 (Aβ40) and amyloid β1-42 (Aβ42), 
have been associated with an increased risk of AD.11–13 
Several studies have indicated that changes in Aβ40 and 
Aβ42 or the ratio of Aβ42 to Aβ40 levels in the blood may 
be associated with depression, but these results have been 
inconclusive.14–17
The objective of this study was to investigate whether 
serum Aβ levels are associated with depressive symptoms 
and/or cognitive function in Japanese community-dwelling 
elderly individuals. We hypothesized that depression among 
older elderly individuals would be more significantly associ-
ated with Aβ than that among younger elderly individuals.
Materials and methods
Participants
The subjects included 419 volunteers 60 years of age and 
over (150 males and 269 females) who participated in the 
Iwaki Health Promotion Project in 2012. The data collection 
for this study was approved by the ethics committee at the 
Hirosaki University School of Medicine, and all subjects 
provided written informed consent before participating in 
the project. Demographic information (age, sex, and level 
of education) was obtained from self-administered question-
naires and interviews. 
Procedure
Blood samples were drawn and centrifuged immediately, and 
serum samples were stored at -80°C until use. A sandwich 
Aβ enzyme-linked immunosorbent assay kit (Wako, Osaka, 
Japan) was employed. The Aβ40 kit uses the BAN50 mono-
clonal antibody, which specifically detects the N-terminal 
portion of human Aβ (residues 1–16), and the BA27 mono-
clonal antibody, which detects the C-terminal portion of 
Aβ40. The Aβ42 kit uses BAN50 and the BC05 monoclonal 
antibody, which detects the C-terminal portion of Aβ42. 
The sensitivity has been reported as 0.019 pmol/L (dynamic 
range, 1.0–100 pmol/L) for Aβ40 and 0.06 pmol/L (dynamic 
range, 0.1–20 pmol/L) for Aβ42.18
 The Mini-Mental State Examination (MMSE) was 
administered to all participants to measure their global cogni-
tive status. This test assesses orientation to place and time, 
short-term memory, episodic long-term memory, subtraction 
ability, ability to construct a sentence, and oral language 
ability. The maximum score is 30, and scores less than 25 
indicate poor cognitive function.19
The Japanese version of the Center for Epidemiologic 
Studies Depression Scale (CES-D) was administered to all 
of the participants to measure their depression symptoms.20,21 
The CES-D is a 20-item self-report measure that focuses on 
depression symptoms during the week prior to administer-
ing the questionnaire. The maximum score on this scale is 
60, and depression is considered present for subjects with 
CES-D scores of 16 or more.
The ability to perform activities of daily living was evalu-
ated using the Tokyo Metropolitan Institute of Gerontology   
Index of Competence (TMIG-IC), a multidimensional 13-item 
scale.22 The TMIG-IC was developed to measure the func-
tional capacity of an independently living elderly subject and 
is composed of three competencies: instrumental self-main-
tenance, intellectual activity, and social role. The TMIG-IC 
has been used in previous studies to examine the functional 
capacity of community-dwelling Japanese elderly.23,24
statistical analysis
Data are presented as the mean ± standard deviation (SD). 
P-values of less than 0.05 were considered to be statistically 
significant. Because prevalence of dementia has increased 
from the 1970s,25 we divided the subjects into age subgroups 
of younger elderly between 60 and 69 years old and older 
elderly over 69 years old. Student’s unpaired t-test was 
used to analyze continuous variables, and a chi-square test 
was performed to analyze categorical variables between 
age subgroups. Pearson product moment correlation was 
used to explore the relationships among depression, cogni-
tive function, and the serum Aβ (Aβ40, Aβ42, and Aβ40/
Aβ42) levels among the total subjects, younger elderly, and 
older elderly. Multiple linear regression was employed for 
the MMSE and CES-D scores to analyze the associations 
among Aβ40, Aβ42, and Aβ40/Aβ42 levels. Regression 
analyses were adjusted for confounding factors (age, sex, 
level of education, and TMIG-IC score).
The data were analyzed using the PASW Statistics soft-
ware for Windows, Version 18.0.0 (SPSS Inc., Chicago, 
IL, USA), and Amos software for Windows, Version 17.0 
(SPSS Inc.).
Results
The demographic characteristics of the subjects are listed in 
Table 1. Compared with the younger elderly subgroup, the 
older elderly subgroup showed a significantly higher age, 
CES-D score, prevalence of hypertension, and level of Aβ40 
and Aβ40/Aβ42, but the older elderly subgroup had a lower 
education level and MMSE score.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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In the Pearson product moment correlation analysis, 
serum Aβ levels were not correlated with MMSE scores 
among the total subjects, younger elderly, or older elderly. 
After controlling for age, sex, level of education, and 
TMIG-IC score, the multiple regression showed that serum 
Aβ levels were not associated with MMSE scores among the 
total subjects, younger elderly, or older elderly (Table 2).
In the Pearson product moment correlation analysis, both 
serum Aβ40 and Aβ42 levels were positively correlated with 
CES-D scores in the older elderly subgroup. After control-
ling for age, sex, level of education, and TMIG-IC score, the 
multiple linear regression showed that both serum Aβ40 and 
Aβ42 levels were positively associated with CES-D scores 
only in the older elderly subgroup (Table 3).
Discussion
This cross-sectional study investigated the relationships 
among depressive symptoms, cognitive function, and serum 
Aβ levels among community-dwelling elderly individuals 
in Japan. We found that serum Aβ40 and Aβ42 levels were 
positively associated with depressive symptoms in the older 
elderly subgroup but not in the younger elderly subgroup. 
Previous studies with a cross-sectional design exploring 
the relationships between depressive symptoms and plasma 
Aβ levels have shown inconsistent results. The first study in 
the US showed that 47 patients with late-life major depression 
had higher plasma Aβ42 levels than 30 younger controls.14 
In another study in Korea among 123 community-dwelling 
elderly subjects, Moon and colleagues used the Short 
  Geriatric Depression Scale-Korean version (SGDS-K) and 
found a positive association between plasma Aβ42 levels and 
depressive symptoms.26 In a population-based cohort of 980 
elderly individuals from Rotterdam, Direk and colleagues 
showed that subjects with higher plasma Aβ40 levels had 
more depressive symptoms on the Center for Epidemiologic 
Studies Depression Scale (CES-D).17 The authors found 
that this cross-sectional association could be explained by 
subjects with depressive symptoms who developed demen-
tia within the 11-year follow-up period. In contrast, several 
cross-sectional studies performed in the Nutrition, Aging, and 
Memory in the Elderly (NAME) study found the opposite 
association: depressed subjects had lower plasma levels of 
Aβ42 than the controls.15,27–29 
Three longitudinal studies have analyzed the association 
between plasma Aβ levels and depression. A report from the 
Vienna Transdanube Aging (VITA) study showed that higher 
plasma Aβ42 levels at baseline predicted the conversion to 
depression among 331 subjects who fulfilled the criteria of 
having no previous history of depression and no dementia or 
depression at baseline.16 Among 988 community-dwelling 
elderly subjects in the US Health Aging and Body Composi-
tion (ABC) study, lower Aβ42/Aβ40 levels at baseline were 
associated with an increased risk of developing depression 
over a 9-year follow-up period, but only in ApoE4 carriers.30   
In another study in the Netherlands that assessed 980 
  community-dwelling elderly subjects with the CES-D, Direk 
Table 1 Demographic characteristics of the subjects
Total subjects 60–69 years old 70 years and older
N 419 246 173
age in years (mean ± sD)* 68.5±6.4 64.0±2.7 75.0±4.3
sex (%)
Male 150 (35.8) 92 (37.4) 58 (33.5)
Female 269 (64.2) 154 (62.6) 115 (66.5)
education (years) (mean ± sD)* 10.8±2.0 11.2±1.7 10.1±2.0
Pack-years of smoking (mean ± sD) 6.6±16.1 7.3±16.1 5.7±16.0
TMig-ic score (mean ± sD) 12.1±1.2 12.1±1.2 12.1±1.2
ces-D score (mean ± sD)* 10.3±6.1 9.7±6.1 11.2±6.0
MMse score (mean ± sD)* 28.2±2.5 28.7±2.1 27.6±2.9
Positive history of 
Diabetes mellitus (%) 44 (10.5) 21 (8.5) 23 (13.3)
hypertension (%)* 196 (46.8) 92 (37.4) 104 (60.1)
Dyslipidemia (%) 87 (20.8) 56 (22.8) 31 (17.9)
aβ40 (pmol/l) (mean ± sD)* 22.0±9.6 20.3±8.9 24.5±10.2
aβ42 (pmol/l) (mean ± sD) 2.0±2.6 2.0±3.3 2.1±0.9
aβ40/aβ42 (mean ± sD)* 11.9±3.7 11.6±3.6 12.4±3.7
Note: *Indicates a significant difference among the subgroups. 
Abbreviations: TMig-ic, Tokyo Metropolitan institute of gerontology index of competence; ces-D, center for epidemiologic studies Depression scale; MMse,   
Mini-Mental state examination; sD, standard deviation; aβ, amyloid beta.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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correlation between serum amyloid β levels and depressive symptoms
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Tsuruga et al
and colleagues also found that low levels of Aβ40 and Aβ42 
without dementia were associated with an increased risk of 
depressive symptoms during the follow-up period.17 Until 
now, studies have not fully supported the view that subclini-
cal depressive symptoms or clinical depression represents a 
risk factor for developing AD through a mechanism involv-
ing an increase or decrease in Aβ in the blood. However, 
we cannot completely rule out the possibility of an amyloid-
related mechanism, as different disease stages of dementia 
occur throughout older age; therefore, the criteria used for 
depression (early onset vs late onset or acute vs chronic) 
and the apolipoprotein E4 allele could lead to changes of 
Aβ in the blood.
In the present study, we found that increased levels of 
serum Aβ40 and Aβ42 levels were associated with higher 
CES-D scores in the older elderly subgroup but not in the 
younger elderly subgroup. A previous study that stratified by 
age subgroup showed that serum Aβ42 levels were lower in 
subjects younger than 40 years old and in subjects older than 
64 years old than in healthy controls, and differences in the 
severity of illness could have affected this difference.31 The 
participants in the study were inpatients who were clinically 
diagnosed with DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders, 4th ed) major depressive disorder. 
Several mechanisms may explain the positive correlation 
relation between serum Aβ levels and depressive symptoms. 
Higher serum Aβ levels might develop the depositions in the 
neurons and in cerebral vessels which may play a role in the 
etiology of depression.32,33 In addition, Aβ aggregations in 
small cerebral vessels can decrease cerebral blood flow and 
glucose utilization.
We found no relationship between cognitive function, 
as measured by the MMSE, and serum Aβ levels. However, 
the MMSE alone may not be sensitive to the subtle cogni-
tive impairment that is present in depression, which may be 
associated with elevated serum Aβ42 levels. Furthermore, 
there is evidence linking executive dysfunction to structural 
and functional brain abnormalities, including white matter 
pathology, in depressed elderly subjects.34 Therefore, we 
cannot completely rule out the relationship between cognitive 
function and the level of Aβ.
The current study has several limitations. First, the 
cross-sectional nature of the study did not allow for causal 
assumptions between serum Aβ levels and depressive symp-
toms; future studies with longitudinal designs are needed to 
investigate these associations. Second, the assessment of 
depression was established by the CES-D rather than by a 
clinician-administered structured diagnostic interview. As a 
result, we collected no information about the onset or course 
of the disease. Third, several potential confounding factors, 
such as marital status, physical illness, and characterization 
of apolipoprotein E4 allele, were not assessed in our study. 
Furthermore, Aβ and depressive symptoms may share com-
mon genetic or environmental risk factors, such as diabetes 
and dyslipidemia, in the causal pathway. Although multiple 
regression analysis was performed, this explanation still 
cannot be excluded. Fourth, as all of the participants were 
volunteers who were interested in their health, they may 
have been healthier than the general population. Thus, the 
members of the community who were not involved in this 
study may have presented different depressive symptoms; 
this selection bias must be considered in future studies of 
community populations.
Conclusion
This study showed that serum Aβ levels were positively 
associated with depressive symptoms among community-
dwelling elderly individuals. The present results support 
the possibility that Aβ in the blood may be involved in the 
development of late-onset depression, although further stud-
ies with longitudinal observations are warranted. 
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